The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration

被引:72
作者
Belloni, Daniela
Scabini, Silvia
Foglieni, Chiara
Veschini, Lorenzo
Giazzon, Alessio
Colombo, Barbara
Fulgenzi, Alessandro
Helle, Karen B.
Ferrero, Maria Elena
Corti, Angelo
Ferrero, Elisabetta
机构
[1] Ist Sci San Raffaele, DIBIT, Cardiovasc Dept, I-20132 Milan, Italy
[2] Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy
[3] Ist Sci San Raffaele, IIT Network Res Unit Mol Neurosci, I-20132 Milan, Italy
[4] Univ Bergen, Dept Biomed, Bergen, Norway
[5] CNR, Inst Gen Pathol, I-20133 Milan, Italy
[6] CNR, Ctr Studies Cellular Pathol, I-20133 Milan, Italy
关键词
ERK/MAPK; capillary-like structures;
D O I
10.1096/fj.06-6829com
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A growing body of evidence suggests that chromogranin A (CgA), a secretory protein released by many neuroendocrine cells and frequently used as a diagnostic and prognostic serum marker for a range of neuroendocrine tumors, is a precursor of several bioactive fragments. This work was undertaken to assess whether the N-terminal fragment CgA(1-76) (called vasostatin I) can inhibit the proangiogenic activity of vascular endothelial growth factor (VEGF), a factor involved in tumor growth. The effect of recombinant human vasostatin I (VS-1) on VEGF-induced human umbilical endothelial cells (HUVEC) signaling, proliferation, migration, and organization has been investigated. We have found that VS-1 (3 mu g/ ml; 330 nM) can inhibit VEGF-induced ERK phosphorylation, as well as cell migration, proliferation, morphogenesis, and invasion of collagen gels in various in vitro assays. In addition, VS-1 could inhibit the formation of capillary-like structures in Matrigel plugs in a rat model. VS-1 could also inhibit basal ERK phosphorylation and motility of HUVEC, leading to a more quiescent state in the absence of VEGF, without inducing apoptotic or necrotic effects. Conclusion: These findings suggest that vasostatin I may play a novel role as a regulator of endothelial cell function and homeostasis.
引用
收藏
页码:3052 / 3062
页数:11
相关论文
共 50 条
  • [1] THE VASOINHIBITORY ACTIVITY OF BOVINE CHROMOGRANIN-A FRAGMENT (VASOSTATIN) AND ITS INDEPENDENCE OF EXTRACELLULAR CALCIUM IN ISOLATED SEGMENTS OF HUMAN BLOOD-VESSELS
    AARDAL, S
    HELLE, KB
    [J]. REGULATORY PEPTIDES, 1992, 41 (01) : 9 - 18
  • [2] The plasminogen activation system in tumor growth, invasion, and metastasis
    Andreasen, PA
    Egelund, R
    Petersen, HH
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) : 25 - 40
  • [3] A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours
    Bernini, GP
    Moretti, A
    Ferdeghini, M
    Ricci, S
    Letizia, C
    D'Erasmo, E
    Argenio, GF
    Salvetti, A
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (05) : 636 - 642
  • [4] Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine
    Blois, A
    Holmsen, H
    Martino, G
    Corti, A
    Metz-Boutigue, MH
    Helle, KB
    [J]. REGULATORY PEPTIDES, 2006, 134 (01) : 30 - 37
  • [5] BLOIS A, 2006, REGUL PEPTIDES, V135, P554
  • [6] Role for extracellular signal-responsive kinase-1 and-2 in retinal angiogenesis
    Bullard, LE
    Qi, X
    Penn, JS
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (04) : 1722 - 1731
  • [7] Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS
    Cai, J
    Jiang, WG
    Ahmed, A
    Boulton, M
    [J]. MICROVASCULAR RESEARCH, 2006, 71 (01) : 20 - 31
  • [8] VEGF as a key mediator of angiogenesis in cancer
    Carmeliet, P
    [J]. ONCOLOGY, 2005, 69 : 4 - 10
  • [9] Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality
    Ceconi, C
    Ferrari, R
    Bachetti, T
    Opasich, C
    Volterrani, M
    Colombo, B
    Parrinello, G
    Corti, A
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 (12) : 967 - 974
  • [10] Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors
    Chow, S
    Patel, H
    Hedley, DW
    [J]. CYTOMETRY, 2001, 46 (02): : 72 - 78